REPS1 and colorectal carcinoma: For targeting neo-epitopes, KISIMA-Mad24, a KISIMA-derived vaccine bearing the previously described neoantigens Adpgk (ADP-dependent glucokinase) and Reps1 (RalBP1-associated Eps domain-containing protein 1) which are expressed in the murine colorectal carcinoma model MC-3828 and the corresponding VSV-GP-Mad24 were used.